UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036119
Receipt number R000041139
Scientific Title A comparative study of renoprotective effect of tolvaptan as an alternative treatment for increasing loop diuretics in patients with chronic kidney disease complicated with chronic heart failure
Date of disclosure of the study information 2019/04/01
Last modified on 2022/08/02 23:11:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A comparative study of renoprotective effect of tolvaptan as an alternative treatment for increasing loop diuretics in patients with chronic kidney disease complicated with chronic heart failure

Acronym

A comparative study of renoprotective effect of tolvaptan as an alternative treatment for increasing loop diuretics in patients with chronic kidney disease complicated with chronic heart failure

Scientific Title

A comparative study of renoprotective effect of tolvaptan as an alternative treatment for increasing loop diuretics in patients with chronic kidney disease complicated with chronic heart failure

Scientific Title:Acronym

A comparative study of renoprotective effect of tolvaptan as an alternative treatment for increasing loop diuretics in patients with chronic kidney disease complicated with chronic heart failure

Region

Japan


Condition

Condition

chronic heart failure, chronic kidney disease

Classification by specialty

Cardiology Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to compare long-term renal prognosis treated with additive tolvaptan vs. increased loop diuretics in chronic kidney disease patients with chronic heart failure.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Serum creatinine level
eGFR change from baseline
Worsening renal function (WRF)
from 1 days to 1 years later

Days until the dialysis induction
Dialysis induction rate

Key secondary outcomes

urine volume, body weight, blood pressure, heart rate, plasma BNP, echocardiography (inferior vena cava diameters, ejection fraction), chest X ray (cardio-thoracic ratio, pulmonary congestion), urine osmolality, Fractional Excretion of Na (FENa), serum BUN, serum Na, serum K , New York heart association cardiac functional classification, cardiovascular event rate


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Tolvaptan group: Add tolvaptan administration

Interventions/Control_2

Furosemide group: Increased furosemide administration

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Heart failure patients over 20 years of age taking over 40 mg/day furosemide with a estimated GFR (eGFR)<45 mL/min/1.73m2.

Key exclusion criteria

Patients who cannot intake fluids or feel thirst
Patients with anuria or urinary excretion disorder
Patients with hypernatremia
Patients with serious hepatic disorder
Patients under the pacing therapy
Patients with percutaneous coronary intervention or open heart surgery within the past 3 months
Patients with poorly controlled diabetes mellitus
Patients who take SGLT-2 inhibitor
Patients who are pregnant or possibly pregnant
Patients without agreement on enrolment of this study
Inappropriate patients judged by doctor

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Hisato
Middle name
Last name Shima

Organization

Kawashima hospital

Division name

Department of Kidney Disease

Zip code

7700011

Address

1-39 Kitasakoichiban-cho, Tokushima city 770-0011, Tokushima, Japan

TEL

088-631-0110

Email

h.shima@khg.or.jp


Public contact

Name of contact person

1st name Hisato
Middle name
Last name Shima

Organization

Kawashima hospital

Division name

Department of Kidney Disease

Zip code

7700011

Address

1-39 Kitasakoichiban-cho, Tokushima city 770-0011, Tokushima, Japan

TEL

088-631-0110

Homepage URL


Email

h.shima@khg.or.jp


Sponsor or person

Institute

Kawashima hospital

Institute

Department

Personal name



Funding Source

Organization

Kawashima hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kawashima hospital

Address

1-39 Kitasakoichiban-cho, Tokushima city 770-0011, Tokushima, Japan

Tel

088-631-0110

Email

h.shima@khg.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2019 Year 03 Month 05 Day

Date of IRB

2019 Year 03 Month 05 Day

Anticipated trial start date

2019 Year 03 Month 07 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 03 Month 07 Day

Last modified on

2022 Year 08 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041139


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name